Evidence map›Paper›PMID 40534669›Full record

ArticleACS pharmacology & translational science2025

The Selective Serotonin 5‑HT

Anders A Jensen, Claudia R Cecchi, Meghan Hibicke, Astrid H Bach, Erik Kaadt, Emil Märcher-Rørsted, Charles D Nichols, Betina Elfving, Jesper L Kristensen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Discovery of Highly Selective 5-HTJournal of medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anders A JensenLophora ApS, 2920 Charlottenlund, Denmark.ORCID https://orcid.org/0000-0002-7927-5052
Claudia R CecchiExperimental and Molecular Psychiatry Group, Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmark.
Meghan HibickeDepartment of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, United States.
Astrid H BachExperimental and Molecular Psychiatry Group, Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmark.
Erik KaadtExperimental and Molecular Psychiatry Group, Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmark.
Emil Märcher-RørstedLophora ApS, 2920 Charlottenlund, Denmark.ORCID https://orcid.org/0000-0002-2783-6655
Charles D NicholsDepartment of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, United States.ORCID https://orcid.org/0000-0002-0615-0646
Betina ElfvingExperimental and Molecular Psychiatry Group, Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmark.
Jesper L KristensenLophora ApS, 2920 Charlottenlund, Denmark.ORCID https://orcid.org/0000-0002-5613-1267

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psychedelics have emerged as a promising treatment for mental health disease, and the therapeutic potential of psilocybin and lysergic acid diethylamide (LSD) is presently being pursued in numerous clinical trials. This has prompted a search for novel agents with more specific pharmacological activities than the rather promiscuous classical psychedelics. Here we present the detailed pharmacological characterization of one such compound, LPH-5 [(

Indexed as

5-HT2A receptorbehavioral studiesclassical psychedelicsdepressionLPH-5subtype-selective

Identifiers

PMID40534669
PMCPMC12171885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.